Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00469755 · ClinicalTrials.gov registry record · Phase 4
Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne
A Phase 4 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 302
- Enrollment target
NCT00469755 is a Phase 4 study that has completed, run by Galderma R&D. The registered enrollment target is 302 participants.
The verdict
NCT00469755, a Phase 4 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 302 participants
- Enrollment target
Study Summary
To determine the efficacy and safety of 12 weeks of treatment with Differin Gel, 0.1% compared to 12 weeks of treatment with Tazorac Cream, 0.1% and compared to 6 weeks treatment with Differin Gel, 0.1% followed by 6 weeks of treatment with Tazorac Cream
Interventions
- DRUG Adapalene Gel, 0.1%
- DRUG Tazarotene Cream, 0.1%
- DRUG Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 302 participants |
| Start Date | 2006-02 |
| Est. Completion | 2006-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00469755
The ClinicalTrials.gov registry entry for NCT00469755 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 302 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Adapalene Gel, 0.1% is the first listed.
NCT00469755 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00469755 about?
NCT00469755 is a clinical study titled "Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne". To determine the efficacy and safety of 12 weeks of treatment with Differin Gel, 0.1% compared to 12 weeks of treatment with Tazorac Cream, 0.1% and compared to 6 weeks treatment with Differin Gel, 0.1% followed by 6 weeks of treatment with Tazorac Cream
What is the current status of trial NCT00469755?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 302 participants. The study started on 2006-02. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00469755?
The interventions under investigation include: Adapalene Gel, 0.1% (DRUG), Tazarotene Cream, 0.1% (DRUG), Adapalene Gel, 0.1% + Tazarotene Cream, 0.1% (DRUG).
Who is sponsoring clinical trial NCT00469755?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.